Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Baccarani, M ^a   Dreyling, M ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CANCER VACCINE; CYTARABINE; DASATINIB; HOMOCETAXINE; HYDROXYUREA; IMATINIB; NILOTINIB; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD CELL COUNT; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FOLLOW UP; HUMAN; LOW DRUG DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

EID: 77954328319     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq201     Document Type: Article

References (21)

1. Baccarani M, Saglio G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an export panel of behalf of the European LeukemiaNet. Blood 2006, 108: 1809-1820
2. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in « good-risk » chronic granulocytic leukemia. Blood 1984, 63: 789-799
3. Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukaemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998, 90: 850-858
4. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348: 994-1004
5. Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349: 1423-1432
6. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Eng J Med 2006; 355: 2408-2417
7. Hochhaus A, O'Brien SG, Guilhot F et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23: 1054-1061
8. Hehlmann R, Berger U, Pfirrmann M et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007, 109: 4686-4692
9. Hughes T, Branford S, While DL et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600mg/day of imatinib as initial therapy. Blood 2008, 112: 3965-3972
10. Baccarani M, Rosti G, Castagnetti F et al. A comparison of imatinib 400 mf and 800 mg daily in the first-line treatment of patients with high risk, philadelphia-positive, chronic myeloid leukemia. A European Leukemia Net Study. Blood 2009, 113: 4497-4504
11. Cortes J, Baccarani M, Guilhot F et al. A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (tyrosine kinase inhibitor optimization and selectivity) study. Blood 2008, 112: 130-131 (Abstr 325)
12. Rousselot P, Huguent F, Rea D et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007, 109: 58-60
13. Talpaz M, Shas NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Eng J Med 2006, 354: 2531-2541
14. Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leucemia after failure of imatinib therapy. Blood 2007, 109: 2303-2309
15. Kantarjian H, Giles F, Wunderle L et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Eng J Med 2006, 354: 2542-2551
16. Kantarjian HM, Giles F, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110: 3540-3546
17. Grigg A, Hughes T. Rose of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biol Blood Marrow Transplant 2006, 12: 795-807
18. Gratwohl A, Brand R, Apperley J et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006, 91: 513-521
19. Heaney NB, Copland M, Stewart K et al. Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia. Blood 2008, 111: 5252-5255
20. Hughes T, Deininger M, Hochhaus A et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for hermonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108: 28-37
21. Baccarani M, Pane F, Saglio G. Monitoring treatment of chronic myeloid leucemia. Haematologica 2008, 93: 161-169